SIL as Maintenance Therapy in Multiple Myeloma

• Status: NOT_YET_RECRUITING
• Trial end date: 2030-01-01

Summary

The goal of this phase 2 trial is to test the safety and efficacy of selinexor combined with ixazomib and lenalidomide as maintenance therapy in patients with multiple myeloma.

• Phase: PHASE2

Details

• Lead Sponsor: Navy General Hospital, Beijing
• Treatments: ixazomib; Lenalidomide; Maintenance